In the previous study conducted by the investigators, it was found that rosiglitazone, which is a PPAR-γ agonist, increased the expression of PPAR-γ around the hematoma in cerebral hemorrhage and improved the neurological function in animal models, thereby providing evidence that NLRP6 might play a role in cerebral hemorrhage [24, 25]. The gene discussed is NLRP6; the disease is hematoma.